Revolution Medicines, Inc.

NASDAQ:RVMD

Biotechnology

Healthcare
$159.82 +2.28%

+$3.60 today

Market cap
$34.57B
Beta
1.41
P/E (TTM)
-23.3
EPS (TTM)
-$6.92
52W Low $34.00High $166.50

Volume 2.34M

Average 3.10M

RVMD Cost of Revenue

Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.

Revolution Medicines, Inc.NASDAQ: RVMD

Cost of Revenue · Q2 FY2026 · quarter ended Jun 2026

Cost of revenue remains negative

Q2 FY2026 cost of revenue was $0, compared with $0 a year earlier. Trailing-twelve-month cost of revenue was $9.24M.

Context

  • Cost of revenue increased in 1 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly cost of revenue holds near $0 or moves back toward the trailing-twelve-month quarterly average of $2.31M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$0-100.0% QoQ
Last fiscal yearDec 2025
$16.56M— YoY
LTMJun 2026
$9.24M— YoY
Cost of Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Cost of Revenue history

USD · from the income statement

Latest · FY2025
16.56M USD
Year-over-year change
—

Cost of Revenue vs competitors

How RVMD compares with its peers on the latest reported figures

  • RVMD's LTM Jun 2026 cost of revenue of $9.24M is the 4th highest of the 11 companies compared; the peer median is $1.75M.
RVMD Competitors Peer median
Cost of Revenue for RVMD and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IDYAIDEAYA Biosciences, Inc.LTM Mar 2026$244.96M +232.7%+29.8%108.7%
NRIXNurix Therapeutics, Inc.LTM Aug 2026$94.76M -56.9%-53.2%13.5%
RLAYRelay Therapeutics, Inc.LTM Jun 2026$68.99M -65.9%-75.5%666.6%
RVMDRevolution Medicines, Inc.LTM Jun 2026$9.24M ———
VSTMVerastem, Inc.LTM Mar 2026$8.06M ——16.3%
GLUEMonte Rosa Therapeutics, Inc.LTM Mar 2026$2.03M -1.5%—4.7%
ERASErasca, Inc.LTM Sep 2026$1.47M +76.2%+5.6%—
TNGXTango Therapeutics, Inc.LTM Sep 2026$942K +50.7%——
ORICORIC Pharmaceuticals, Inc.LTM Mar 2026$320K +5.3%——
BDTXBlack Diamond Therapeutics, Inc.LTM Mar 2026$113K +31.4%——
ELVNEnliven Therapeutics, Inc.LTM Sep 2026$60K ———
Peer median (excluding RVMD) $1.75M+18.3%-23.8%16.3%

Competitors are the stored peer set for RVMD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue29.39M35.38M11.58M00
Cost of Revenue000016.56M
Gross Profit29.39M35.38M11.58M0(16.56M)
Gross Margin100.0%100.0%100.0%——
Research & Development186.95M253.07M423.14M592.23M978.68M
Selling, General & Admin30.45M40.59M75.62M97.3M187.13M
Operating Expenses217.4M293.66M498.77M689.52M1.17B
Depreciation & Amortization7.33M9.66M9.31M11.82M16.56M
EBITDA(179.75M)(239.47M)(430.28M)(589.02M)(1.09B)
EBITDA Margin-611.6%-676.8%-3715.7%——
Operating Income(188.01M)(258.28M)(487.19M)(689.52M)(1.18B)
Operating Margin-639.7%-730.0%-4207.1%——
Interest Income929K9.15M47.48M86.88M90.69M
Interest Expense12K0303K024.23M
Other Income / Expenses917K9.15M47.29M88.68M51.07M
Income Before Tax(187.09M)(249.13M)(439.89M)(600.85M)(1.13B)
Pre-Tax Margin-636.6%-704.1%-3798.7%——
Income Tax Expense0(420K)(3.52M)(753K)0
Net Income(187.09M)(248.71M)(436.37M)(600.09M)(1.13B)
Net Margin-636.6%-703.0%-3768.3%——
EPS (Basic)(2.47)(3.08)(3.86)(3.58)(5.95)
EPS (Diluted)(2.47)(3.08)(3.86)(3.58)(5.95)
Weighted Avg Shares72.81M80.63M113.15M167.74M190.13M
Weighted Avg Shares (Diluted)72.81M80.63M113.15M167.74M190.13M

Revolution Medicines, Inc.

NASDAQ:RVMD

Intrinsic Alpha fair value

Locked

Current Price

$159.82

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.